Probiotix Health

Probiotix Health ROCE

The Return on Capital Employed (ROCE) of Probiotix Health (PBX.AQ) as of Nov 20, 2026 is -85.79 %. In the previous year, Return on Capital Employed (ROCE) was -43.63 % — a change of 96.64% (lower).

ROCE

-85.79 %

YoY

96.64%

Last updated:

In 2025, Probiotix Health's return on capital employed (ROCE) was -85.79 %, a 96.64% increase from the -43.63 % ROCE in the previous year.

The Probiotix Health ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
105.87 GBP
Jan 1, 2020
-10.12 GBP
Jan 1, 2021
-25.18 GBP
Jan 1, 2022
-6.68 GBP
Jan 1, 2023
-46.96 GBP
Jan 1, 2024
-43.63 GBP
Jan 1, 2025
-85.79 GBP
The Probiotix Health ROCE history
YEARROCEYoY
-85.79 %+96.64%
-43.63 %-7.10%
-46.96 %+603.21%
-6.68 %-73.48%
-25.18 %+148.85%
-10.12 %-109.56%
105.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Probiotix Health Stock analysis

What does Probiotix Health do? ProBiotix Health PLC develops probiotics to tackle cardiovascular disease and lifestyle conditions, focusing on cholesterol reduction through its LP-LDL ingredient. The company commercializes LP-LDL as an ingredient and in CholBiome products, including CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH, which improve blood lipid profiles and blood pressure. ProBiotix leverages its OptiScreen and OptiBiotic platform technologies to identify metabolic pathways for potential health benefits across various diseases. The firm targets healthcare providers, supplement manufacturers, and consumers seeking natural solutions for cardiovascular health. ProBiotix Health PLC's revenue streams include selling LP-LDL as an ingredient to manufacturers and direct sales of CholBiome products under white-label and own-label arrangements. The CholBiome range serves segments such as cardiovascular health management, lifestyle disease prevention, and natural health supplements. The company's pipeline, driven by OptiScreen and OptiBiotic, supports future product development in metabolic health and disease-specific applications. The firm's business model centers on developing and commercializing probiotic solutions for cardiovascular health, with LP-LDL as the core product. CholBiome products are positioned for consumers and healthcare partners, while the OptiScreen and OptiBiotic platforms enable expansion into new therapeutic areas. ProBiotix's revenue comes from ingredient sales and branded product lines targeting health-conscious individuals and industry partners in the probiotic and supplement markets. Probiotix Health is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Probiotix Health's Return on Capital Employed (ROCE)

Probiotix Health's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Probiotix Health's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Probiotix Health's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Probiotix Health’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Probiotix Health stock

Return on Capital Employed (ROCE) of Probiotix Health is -85.79 % in 2025.

Return on Capital Employed (ROCE) of Probiotix Health changed from -43.63 % to -85.79 %, representing a 96.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Probiotix Health since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Probiotix Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Probiotix Health

All Key Metrics — Probiotix Health